The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 24, 2024
Filed:
Mar. 15, 2019
Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;
Universite DE Paris, Paris, FR;
Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;
Ecole Superieure DE Physique ET DE Chimie Industrielles DE LA Ville DE Paris, Paris, FR;
Roberto Mallone, Paris, FR;
Sergio Gonzalez-Duque, Paris, FR;
Yann Verdier, Paris, FR;
Marie-Eliane Azoury, Paris, FR;
Georgia Afonso, Paris, FR;
Joëlle Vinh, Paris, FR;
Abstract
Despite the notion that human CD8T cells are the final mediators of autoimmune β-cell destruction in type 1 diabetes (T1D), none of their target epitopes has been demonstrated to be naturally processed and presented by β cells. The inventors therefore performed an epitope discovery study combining HLA Class I peptidomics and transcriptomics strategies. Inflammatory cytokines increased β-cell peptide presentation in vitro, paralleling upregulation of HLA Class I expression. Peptide sources included known β-cell antigens and several insulin granule proteins. Urocortin 3 was identified as a novel β-cell antigen, which was processed into HLA-A2- and HLA-A3-restricted epitopes recognized by circulating naive CD8T cells in type 1 diabetic and healthy donors. Accordingly, the present invention relates to antigenic peptides derived from urocortin-3 and uses thereof for the diagnosis and treatment of T1D.